{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T08:30:18Z","timestamp":1769070618605,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,11]]},"DOI":"10.7759\/cureus.69149","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T08:11:40Z","timestamp":1726042300000},"source":"Crossref","is-referenced-by-count":1,"title":["Castleman Disease: A Rare Lymphoproliferative Disorder With Diverse Clinical Presentation, Diagnosis, and Treatment Approach"],"prefix":"10.7759","author":[{"given":"Jay P","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deep P","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trishul H","family":"Amin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rushikesh K","family":"Dave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daksh","family":"Hardaswani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faizanali","family":"Saiyed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rushita J","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri A","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020, 135:1353-64. 10.1182\/blood.2019000931","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum DC","year":"2017","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A, et al.. International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood. 2017, 129:1646-57. 10.1182\/blood-2016-10-746933","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.09.001","article-title":"Epidemiology of Castleman disease","volume":"32","author":"Simpson D","year":"2018","unstructured":"Simpson D. Epidemiology of Castleman disease. Hematol Oncol Clin North Am. 2018, 32:1-10. 10.1016\/j.hoc.2017.09.001","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-019-0238-0","article-title":"Imaging and clinical features of Castleman disease","volume":"19","author":"Zhao S","year":"2019","unstructured":"Zhao S, Wan Y, Huang Z, Song B, Yu J. Imaging and clinical features of Castleman disease. Cancer Imaging. 2019, 19:53. 10.1186\/s40644-019-0238-0","journal-title":"Cancer Imaging"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.09.002","article-title":"Castleman disease pathogenesis","volume":"32","author":"Fajgenbaum DC","year":"2018","unstructured":"Fajgenbaum DC, Shilling D. Castleman disease pathogenesis. Hematol Oncol Clin North Am. 2018, 32:11-21. 10.1016\/j.hoc.2017.09.002","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2024.2357689","article-title":"Immunology and targeted therapy in Castleman disease","volume":"20","author":"Tsunoda S","year":"2024","unstructured":"Tsunoda S, Harada T, Kikushige Y, Kishimoto T, Yoshizaki K. Immunology and targeted therapy in Castleman disease. Expert Rev Clin Immunol. 2024, 20:1101-12. 10.1080\/1744666X.2024.2357689","journal-title":"Expert Rev Clin Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0323-6","article-title":"Recurrent PDGFRB mutations in unicentric Castleman disease","volume":"33","author":"Li Z","year":"2019","unstructured":"Li Z, Lan X, Li C, et al.. Recurrent PDGFRB mutations in unicentric Castleman disease. Leukemia. 2019, 33:1035-8. 10.1038\/s41375-018-0323-6","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02105","article-title":"Mechanisms of regulated and dysregulated CARD11 signaling in adaptive immunity and disease","volume":"9","author":"Bedsaul JR","year":"2018","unstructured":"Bedsaul JR, Carter NM, Deibel KE, et al.. Mechanisms of regulated and dysregulated CARD11 signaling in adaptive immunity and disease. Front Immunol. 2018, 9:2105. 10.3389\/fimmu.2018.02105","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1507459112","article-title":"Lymphomagenic CARD11\/BCL10\/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-\u03baB and JNK activation","volume":"112","author":"Knies N","year":"2015","unstructured":"Knies N, Alankus B, Weilemann A, et al.. Lymphomagenic CARD11\/BCL10\/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-\u03baB and JNK activation. Proc Natl Acad Sci U S A. 2015, 112:E7230-8. 10.1073\/pnas.1507459112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/biology10040251","article-title":"A review of genetic abnormalities in unicentric and multicentric Castleman disease","volume":"10","author":"Butzmann A","year":"2021","unstructured":"Butzmann A, Kumar J, Sridhar K, Gollapudi S, Ohgami RS. A review of genetic abnormalities in unicentric and multicentric Castleman disease. Biology (Basel). 2021, 10:251. 10.3390\/biology10040251","journal-title":"Biology (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176173","article-title":"Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation","volume":"12","author":"Kagan P","year":"2017","unstructured":"Kagan P, Sultan M, Tachlytski I, Safran M, Ben-Ari Z. Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation. PLoS One. 2017, 12:e0176173. 10.1371\/journal.pone.0176173","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2014.12.026","article-title":"Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection","volume":"42","author":"Pinzone MR","year":"2015","unstructured":"Pinzone MR, Berretta M, Cacopardo B, Nunnari G. Epstein-barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection. Semin Oncol. 2015, 42:258-71. 10.1053\/j.seminoncol.2014.12.026","journal-title":"Semin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-05235-2","article-title":"Clinical features and treatment outcomes of Castleman disease in children: a retrospective cohort in China","volume":"182","author":"Hu S","year":"2023","unstructured":"Hu S, Li Z, Wang H, et al.. Clinical features and treatment outcomes of Castleman disease in children: a retrospective cohort in China. Eur J Pediatr. 2023, 182:5519-30. 10.1007\/s00431-023-05235-2","journal-title":"Eur J Pediatr"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/mrcr\/rxac034","article-title":"Short stature as an initial presenting presentation of unicentric Castleman disease in a child: a case report with long-term follow-up and a literature review","volume":"7","author":"Sonoda K","year":"2023","unstructured":"Sonoda K, Kaneko U, Hiura M, et al.. Short stature as an initial presenting presentation of unicentric Castleman disease in a child: a case report with long-term follow-up and a literature review. Mod Rheumatol Case Rep. 2023, 7:261-6. 10.1093\/mrcr\/rxac034","journal-title":"Mod Rheumatol Case Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3960\/jslrt.53.69","article-title":"Clinical features and treatment of multicentric castleman's disease : a retrospective study of 21 Japanese patients at a single institute","volume":"53","author":"Kawabata H","year":"2013","unstructured":"Kawabata H, Kadowaki N, Nishikori M, et al.. Clinical features and treatment of multicentric castleman's disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop. 2013, 53:69-77. 10.3960\/jslrt.53.69","journal-title":"J Clin Exp Hematop"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone A","year":"2021","unstructured":"Carbone A, Borok M, Damania B, et al.. Castleman disease. Nat Rev Dis Primers. 2021, 7:84. 10.1038\/s41572-021-00317-7","journal-title":"Nat Rev Dis Primers"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28923","article-title":"KSHV-associated multicentric Castleman disease: a tangle of different entities requiring multitarget treatment strategies","volume":"137","author":"Carbone A","year":"2015","unstructured":"Carbone A, De Paoli P, Gloghini A, Vaccher E. KSHV-associated multicentric Castleman disease: a tangle of different entities requiring multitarget treatment strategies. Int J Cancer. 2015, 137:251-61. 10.1002\/ijc.28923","journal-title":"Int J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04762-6","article-title":"Castleman disease and TAFRO syndrome","volume":"101","author":"Masaki Y","year":"2022","unstructured":"Masaki Y, Arita K, Sakai T, Takai K, Aoki S, Kawabata H. Castleman disease and TAFRO syndrome. Ann Hematol. 2022, 101:485-90. 10.1007\/s00277-022-04762-6","journal-title":"Ann Hematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.5046-20","article-title":"Interleukin-6-producing intravascular large B-cell lymphoma with lymphadenopathy mimicking the histology of multicentric Castleman disease","volume":"59","author":"Shiroshita K","year":"2020","unstructured":"Shiroshita K, Kikuchi T, Okayama M, et al.. Interleukin-6-producing intravascular large B-cell lymphoma with lymphadenopathy mimicking the histology of multicentric Castleman disease. Intern Med. 2020, 59:3061-5. 10.2169\/internalmedicine.5046-20","journal-title":"Intern Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25495","article-title":"POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Dispenzieri A","year":"2019","unstructured":"Dispenzieri A. POEMS syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019, 94:812-27. 10.1002\/ajh.25495","journal-title":"Am J Hematol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/jiaps.jiaps_214_23","article-title":"Unicentric portocaval Castleman disease in an adolescent: challenges in diagnosis and management","volume":"29","author":"Mathew P","year":"2024","unstructured":"Mathew P, Mandelia A, Kumar T, Pal L, Khati S. Unicentric portocaval Castleman disease in an adolescent: challenges in diagnosis and management. J Indian Assoc Pediatr Surg. 2024, 29:174-6. 10.4103\/jiaps.jiaps_214_23","journal-title":"J Indian Assoc Pediatr Surg"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac481","article-title":"Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis","volume":"62","author":"Gonz\u00e1lez Garc\u00eda A","year":"2023","unstructured":"Gonz\u00e1lez Garc\u00eda A, Fern\u00e1ndez-Mart\u00edn J, Robles Marhuenda \u00c1. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis. Rheumatology (Oxford). 2023, 62:1426-35. 10.1093\/rheumatology\/keac481","journal-title":"Rheumatology (Oxford)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.10.013","article-title":"Castleman's disease, pathophysiology, advances in diagnosis and treatment","volume":"162","author":"Pertusa Mataix R","year":"2024","unstructured":"Pertusa Mataix R, Loaiza Cabello D, Garc\u00eda Morillo JS. Castleman's disease, pathophysiology, advances in diagnosis and treatment. Med Clin (Barc). 2024, 162:283-90. 10.1016\/j.medcli.2023.10.013","journal-title":"Med Clin (Barc)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2022.01.045","article-title":"Radiology of Castleman disease: the pivotal role of imaging in diagnosis, staging, and response assessment of this rare entity","volume":"77","author":"Din F","year":"2022","unstructured":"Din F, Mellor F, Millard T, et al.. Radiology of Castleman disease: the pivotal role of imaging in diagnosis, staging, and response assessment of this rare entity. Clin Radiol. 2022, 77:399-408. 10.1016\/j.crad.2022.01.045","journal-title":"Clin Radiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-021-00963-1","article-title":"Emerging role of 18F-FDG PET\/CT in Castleman disease: a review","volume":"12","author":"Koa B","year":"2021","unstructured":"Koa B, Borja AJ, Aly M, et al.. Emerging role of 18F-FDG PET\/CT in Castleman disease: a review. Insights Imaging. 2021, 12:35. 10.1186\/s13244-021-00963-1","journal-title":"Insights Imaging"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205526","article-title":"IgG4-related disease: what a hematologist needs to know","volume":"104","author":"Chen LY","year":"2019","unstructured":"Chen LY, Mattman A, Seidman MA, Carruthers MN. IgG4-related disease: what a hematologist needs to know. Haematologica. 2019, 104:444-55. 10.3324\/haematol.2018.205526","journal-title":"Haematologica"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0134","article-title":"Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman disease","volume":"21","author":"Casper C","year":"2015","unstructured":"Casper C, Chaturvedi S, Munshi N, et al.. Analysis of inflammatory and anemia-related biomarkers in a randomized, double-blind, placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric Castleman disease. Clin Cancer Res. 2015, 21:4294-304. 10.1158\/1078-0432.CCR-15-0134","journal-title":"Clin Cancer Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.5152\/TurkThoracJ.2018.18066","article-title":"Biologic agents in the treatment of multicentric Castleman disease","volume":"19","author":"Kapriniotis K","year":"2018","unstructured":"Kapriniotis K, Lampridis S, Mitsos S, Patrini D, Lawrence DR, Panagiotopoulos N. Biologic agents in the treatment of multicentric Castleman disease. Turk Thorac J. 2018, 19:220-5. 10.5152\/TurkThoracJ.2018.18066","journal-title":"Turk Thorac J"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.09.007","article-title":"Treatment of Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"32","author":"Lurain K","year":"2018","unstructured":"Lurain K, Yarchoan R, Uldrick TS. Treatment of Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. Hematol Oncol Clin North Am. 2018, 32:75-88. 10.1016\/j.hoc.2017.09.007","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003334","article-title":"International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease","volume":"4","author":"van Rhee F","year":"2020","unstructured":"van Rhee F, Oksenhendler E, Srkalovic G, et al.. International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease. Blood Adv. 2020, 4:6039-50. 10.1182\/bloodadvances.2020003334","journal-title":"Blood Adv"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1159\/000526640","article-title":"Recent advances in Castleman disease","volume":"45","author":"Hoffmann C","year":"2022","unstructured":"Hoffmann C, Hentrich M, Tiemann M, Rosenwald A, Weber F, Willenbacher W, H\u00fcbel K. Recent advances in Castleman disease. Oncol Res Treat. 2022, 45:693-704. 10.1159\/000526640","journal-title":"Oncol Res Treat"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn.1009-2137.2023.01.022","article-title":"[Clinical features and prognosis of patients with Castleman\u2019s disease] (Article in Chinese)","volume":"31","author":"Huang XJ","year":"2023","unstructured":"Huang XJ, Zhang XL, Wei XF, et al.. [Clinical features and prognosis of patients with Castleman\u2019s disease] (Article in Chinese). Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023, 31:135-40. 10.19746\/j.cnki.issn.1009-2137.2023.01.022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/2324709617725094","article-title":"Recurrent inflammatory flares in HIV-infected patients: consider Castleman disease!","volume":"5","author":"Jegerlehner S","year":"2017","unstructured":"Jegerlehner S, Rauch A, Novak U. Recurrent inflammatory flares in HIV-infected patients: consider Castleman disease!. J Investig Med High Impact Case Rep. 2017, 5:2324709617725094. 10.1177\/2324709617725094","journal-title":"J Investig Med High Impact Case Rep"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/295416-castleman-disease-a-rare-lymphoproliferative-disorder-with-diverse-clinical-presentation-diagnosis-and-treatment-approach","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T08:11:45Z","timestamp":1726042305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/295416-castleman-disease-a-rare-lymphoproliferative-disorder-with-diverse-clinical-presentation-diagnosis-and-treatment-approach"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.69149","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,11]]}}}